Fat-Blocking Drug Can Help Fight Obesity

July 1999
FDA Consumer;Jul/Aug99, Vol. 33 Issue 4, p2
Reports on the anti-obesity Xenical made by Roche Laboratories Inc. that works by blocking the body's absorption of fat. Results of the long-term clinical trials on the lipase inhibitor; Diet of a patient during treatment; Common side effects of the drug.


Related Articles

  • Fighting fat.  // Drug Topics;6/2/97, Vol. 141 Issue 11, p30 

    Reports on the US Food and Drug Administration's approval of Hoffmann-La Roche's anti-obesity drug Xenical.

  • Roche resubmits Xenical NDA in face of phen-fen legal action.  // Medical Marketing & Media;Dec97, Vol. 32 Issue 12, p24 

    Reports that Hoffmann-La Roche has resubmitted its new drug application for the anti-obesity drug Xenical or orlistat at the US Food and Drug Administration. Mechanism of action of Xenical; Recall of the anti-obesity drugs Pondimin and Redux.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

  • Novel drug promotes weight loss, reduces obesity-related risks. Portyansky, Elena // Drug Topics;5/17/99, Vol. 143 Issue 9, p27 

    Focuses on Xenical, an antiobesity drug from Hoffmann-La Roche. Weight-loss benefits of orlistat; Side-effects of the drug; Information on minimizing the drug's side-effects. INSET: Tips to Remember.

  • Roche Looks for New Spin on Xenical.  // Pharmaceutical Executive;May2000, Vol. 20 Issue 5, p154 

    Announces the search of Hoffman-La Roche for an advertising agency to promote its antiobesity drug Xenical. Revenues generated by sales of the drug for the first quarter of 2000; Advertising expenditures of the company for the drug; Media buys that the company initiated.

  • Roche picks Lowe shops for new anti-obesity drug. Gleason, Mark; Wilke, Michael // Advertising Age;10/14/1996, Vol. 67 Issue 42, p60 

    Tells that Roche Laboratories chose a team of advertising agencies to handle the launch of a new prescription anti-obesity treatment. Roche's orlistat, to be marketed under the name Xenical; Aggressive marketing plan; Pending approval from the US Food & Drug Administration; Comparision to other...

  • DSM Chemie Linz is ready for Roche.  // Chemical Market Reporter;09/01/97, Vol. 252 Issue 9, p4 

    Reports on DSM Fine Chemicals' Chemie Linz's contract to produce hydroxy-beta-lactone, a key intermediate to orlistat, Hoffman-La Roche AG's lipase-inhibitor drug in Linz, Austria. Terms of the multi-year production contract; Estimated cost of Hoffman-La Roche's investment for the multi-step...

  • Orlistat patients offered weight-loss support guidelines. Beyzarov, Elena Portyansky // Drug Topics;5/1/2000, Vol. 144 Issue 9, p32 

    Focuses on a health program from Hoffmann-La Roche company which helps patients taking the diet drug Xenical set realistic expectations on weight loss. Paraphernalia included in the starter kit; Information on the obesity management guidelines.

  • FDA querying neoplasms in Xenical trials. Dickinson, James G. // Medical Marketing & Media;Jul97, Vol. 32 Issue 7, p28 

    Details the findings of the US Food and Drug Administration's clinical trials for orlistat, Hoffman-La Roche's anti-obesity Xenical. Incidence of breast neoplasms in the clinical trials of orlistat.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics